http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109776553-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_653c418e41edbb4e1ce8bc5e53e70cec |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4748 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7385d026cef7e92ccda77e028914faa1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7755a44fc3c362331d3c69a78836438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19ecc1f93cbdcbd2b487aa05c8cb7680 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93aaf151ae5286cfd7ecc00be19e2f54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f629d02dc89892a02a4d2d7afe630f94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_703c9549715da61a549610c8a797cf7d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d33ea45348e77cd4b201af6860c34b3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6fe5f1ec3bc64306a24f88c6cba32cc1 |
| publicationDate | 2019-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109776553-A |
| titleOfInvention | Fuhexine and its preparation method and application |
| abstract | The present invention provides a kind of foxazine and its preparation method and application, and it has the structure shown in formula (I) or formula (I'): Wherein, R is a substituted benzyl group or a substituted pyridylmethyl group; wherein, the substituted benzyl group is a benzyl group substituted by one or more substituents selected from halogen, alkyl, alkoxy, and haloalkyl , the substituted pyridylmethyl group is a halogen-substituted pyridylmethyl group; Y is selected from inorganic acids and organic acids. Due to the bisbenzylisoquinoline core structure and the characteristics of fluorine-substituted benzyl or fluorine-substituted pyridylmethyl, these compounds can effectively inhibit the proliferation of cholangiocarcinoma cells QBC-939 and human pancreatic cancer cells PANC-1 at 0.2 μg/mL. The inhibition rate of fluorouracil is generally higher than 62%, and the inhibition rate of most compounds is generally higher than 80%, and the activity is much higher than that of fluorouracil currently used in clinical practice. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113768873-A |
| priorityDate | 2019-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 201.